PT  - JOURNAL ARTICLE
AU  - Gentile, Ivan
AU  - Maraolo, Alberto Enrico
AU  - Buonomo, Antonio Riccardo
AU  - Nobile, Mariano
AU  - Piscitelli, Prisco
AU  - Miani, Alessandro
AU  - Moriello, Nicola Schiano
TI  - Monoclonal antibodies against SARS-CoV-2: potential game-changer still underused
AID  - 10.1101/2021.09.27.21264191
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.27.21264191
4099  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264191.short
4100  - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264191.full
AB  - Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still in considerable numbers in many nations. Monoclonal antibodies are the ideal complement to vaccination in high-risk subjects who have been infected by SARS-CoV-2 and are at high risk of developing severe disease. Combining data provided by clinal trials and demographics of SARS-CoV-2 infections, this analysis tries to predict the benefits of an extensive use of monoclonal antibodies to reduce hospital admissions, deaths, and costs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data utilized in this article are publically available.